Patents by Inventor Abhimanyu Garg

Abhimanyu Garg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT
    Publication number: 20200268853
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 27, 2020
    Inventors: Alexander M. DePaoli, Elif A. Oral, Simeon I. Taylor, Abhimanyu Garg
  • USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD OF DETERMINING PREDISPOSITION TO SAID TREATMENT
    Publication number: 20190321447
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: November 19, 2018
    Publication date: October 24, 2019
    Inventors: Alexander M. DePaoli, Elif A. Oral, Simeon I. Taylor, Abhimanyu Garg
  • USE OF LEPTIN FOR TREATING HUMAN LIPOATROPHY AND METHOD FOR DETERMINING PREDISPOSITION TO SAID TREATMENT
    Publication number: 20170095535
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: May 13, 2016
    Publication date: April 6, 2017
    Inventors: Alexander M. Depaoli, Elif A. Oral, Simeon I. Taylor, Abhimanyu Garg
  • Use of Leptin for Treating Human Lipoatrophy and Method of Determining Predisposition to Said Treatment
    Publication number: 20130190225
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: November 5, 2012
    Publication date: July 25, 2013
    Inventors: Alexander M. DePaoli, Elif Ariogiu Oral, Simeon I. Taylor, Abhimanyu Garg
  • Use of leptin to treat metabolic abnormalities associated with lipoatrophy
    Patent number: 8318666
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: November 27, 2012
    Assignees: Amgen, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, Board of Regents, The University of Texas System
    Inventors: Alexander M. DePaoli, Elif Arioglu Oral, Simeon I. Taylor, Abhimanyu Garg
  • Use of Leptin for Treating Human Lipoatrophy and Method of Determining Predisposition to Said Treatment
    Publication number: 20110306540
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: May 9, 2011
    Publication date: December 15, 2011
    Inventors: Alexander M. DePaoli, Simeon I. Taylor, Elif A. Oral, Abhimanyu Garg
  • Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
    Publication number: 20070099836
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: November 29, 2006
    Publication date: May 3, 2007
    Applicants: Amgen, Inc., The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human Services, Board of Regents, The University of Texas System
    Inventors: Alexander DePaoli, Simeon Taylor, Elif Oral, Abhimanyu Garg
  • Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
    Patent number: 7183254
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: February 27, 2007
    Assignee: Amgen, Inc.
    Inventors: Alexander M. DePaoli, Simeon I. Taylor, Elif A. Oral, Abhimanyu Garg
  • Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
    Publication number: 20050020496
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: July 18, 2003
    Publication date: January 27, 2005
    Inventors: Alexander DePaoli, Simeon Taylor, Elif Oral, Abhimanyu Garg